Atorvastatin

Generic Name
Atorvastatin
Brand Names
Atorvaliq, Caduet, Lipitor, Lypqozet
Drug Type
Small Molecule
Chemical Formula
C33H35FN2O5
CAS Number
134523-00-5
Unique Ingredient Identifier
A0JWA85V8F
Background

Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...

Indication

Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...

Associated Conditions
Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
Associated Therapies
-
Clinical Trials
Related News

The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males

Phase 4
Completed
Conditions
Ischemia
Interventions
Drug: Placebo
Drug: Atorvastatin
Drug: Ticagrelor
First Posted Date
2016-09-22
Last Posted Date
2017-03-22
Lead Sponsor
Medical University of Vienna
Target Recruit Count
32
Registration Number
NCT02910778
Locations
🇦🇹

Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria

Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease

Phase 4
Completed
Conditions
Chronic Kidney Disease
Interventions
Drug: Atorvastatin
Drug: Pitavastatin
First Posted Date
2016-08-11
Last Posted Date
2021-09-21
Lead Sponsor
Dong-A University
Target Recruit Count
45
Registration Number
NCT02863185
Locations
🇰🇷

Won Suk An, Busan, Korea, Republic of

🇰🇷

Dong-A University, Busan, Korea, Republic of

Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

First Posted Date
2016-07-29
Last Posted Date
2022-11-04
Lead Sponsor
Columbia University
Target Recruit Count
31
Registration Number
NCT02850081
Locations
🇺🇸

Albany Medical College/The Vascular Group at Albany, Albany, New York, United States

🇺🇸

Valley Hospital, Ridgewood, New Jersey, United States

🇺🇸

State University of New York at Buffalo, Buffalo, New York, United States

and more 4 locations

Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension

First Posted Date
2016-07-22
Last Posted Date
2022-04-13
Lead Sponsor
Sanofi
Target Recruit Count
11
Registration Number
NCT02842359
Locations
🇰🇷

Korea, Seoul, Korea, Republic of

Locally Delivered Atorvastatin & Rosuvastatin for Treatment of Furcation Defects in Chronic Periodontitis

First Posted Date
2016-06-15
Last Posted Date
2016-06-15
Lead Sponsor
Government Dental College and Research Institute, Bangalore
Target Recruit Count
90
Registration Number
NCT02800902
Locations
🇮🇳

Government Dental College and Research Institute, Bangalore, Karnataka, India

Statin Therapy In Patients With Vasospastic Angina

First Posted Date
2016-06-06
Last Posted Date
2017-06-15
Lead Sponsor
Seung-Jung Park
Registration Number
NCT02790528
Locations
🇰🇷

Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of

A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium

Early Phase 1
Completed
Conditions
Endometrial Cancer
Interventions
Drug: Atorvastatin
First Posted Date
2016-05-10
Last Posted Date
2020-07-07
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
24
Registration Number
NCT02767362
Locations
🇺🇸

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED)

Not Applicable
Withdrawn
Conditions
Complication of Renal Dialysis
Interventions
Drug: Atorvastatin
First Posted Date
2016-05-06
Last Posted Date
2017-05-18
Lead Sponsor
Albert Einstein Healthcare Network
Registration Number
NCT02764736

Drug Interaction Study of MGL-3196 With Atorvastatin

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Atorvastatin
Drug: MGL-3196
First Posted Date
2016-04-25
Last Posted Date
2016-08-30
Lead Sponsor
Madrigal Pharmaceuticals, Inc.
Target Recruit Count
14
Registration Number
NCT02749578
Locations
🇺🇸

Celerion, Tempe, Arizona, United States

CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction

First Posted Date
2016-04-15
Last Posted Date
2024-10-09
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
79
Registration Number
NCT02740699
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy